Table.

Ongoing Phase 2 and 3 Clinical Trials Evaluating GA lesions Registered on ClinicalTrials.gov as of March 1, 2016

Study Name, NCT Identifier	Study Type	Enrollment	Primary Outcome Measure*
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA), NCT02247479	Phase 3 Interventional	936	Change in GA area, as assessed by FAF
A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (SPECTRI), NCT02247531	Phase 3 Interventional	936	Change in GA area, as assessed by FAF
A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) With Placebo for the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration (SEATTLE), NCT01802866	Phase 2b/3 Interventional	480	Change in GA area
A Randomized, Double Blind, Placebo Controlled Study Evaluating ORACEA® in Subjects With Geographic Atrophy Secondary to Non-Exudative Age-Related Macular Degeneration (TOGA), NCT01782989	Phase 2/3 Interventional	286	Rate of enlargement in area of geographic atrophy in the study eye during the treatment period
A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration (BEACON), NCT02087085	Phase 2 Interventional	300	Change from baseline in atrophic lesion area in the study eye
A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy (PRELUDE), NCT02659098	Phase 2 Interventional	255	Change in GA lesion growth as measured by FAF (secondary endpoint)
Study of APL-2 Therapy in Patients Geographic Atrophy (FILLY), NCT02503332	Phase 2 Interventional	240	Change in square root GA lesion size from baseline, as measured by FAF
Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration, NCT01342926	Phase 2 Interventional	184	Rate of change in area of GA from baseline
CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA), NCT02515942	Phase 2 Interventional	114	(1) Safety events and (2) change in GA lesion size from baseline, as measured by FAF
A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Patients With Geographic Atrophy, NCT02288559	Phase 2 Interventional	90	Mean change in GA area, as measured by FAF
The Effect of Metformin on the Progression of Geographic Atrophy in Patients With Age-related Macular Degeneration, NCT02684578	Phase 2 Interventional	100	Change in GA area as measured by FAF
Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration, NCT02564978	Phase 2 Interventional	62	Rate of change in GA area as measured by FAF
A Multicenter, Prospective Epidemiologic Study of the Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration (PROXIMA-A), NCT02479386	Observational	360	Primary outcomes evaluate visual function; secondary outcomes include measurement of GA area by FAF
Prospective Natural History Study of Fundus Autofluorescence Imaging in Age-related Macular Degeneration (FAM-Study) Using Confocal Scanning Laser Ophthalmoscopy, NCT00393692	Observational	300	Change of GA size from baseline, as assessed by FAF
An Epidemiologic Study of Disease Progression in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (Proxima B), NCT02399072	Observational	200	Change in GA area, as assessed by FAF
Directional Spread in Geographic Atrophy (DSGA), NCT02051998	Observational	130	Change of GA size from baseline

^*Unless otherwise specified as a secondary endpoint